---
layout: default
title: Basiliximab
parent: 僅模型預測 (L5)
nav_order: 119
evidence_level: L5
indication_count: 0
---

# Basiliximab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Basiliximab: Drug Repurposing Evaluation Report

## One-Sentence Summary

Basiliximab is a chimeric monoclonal antibody targeting the IL-2 receptor α chain (CD25), primarily used for prophylaxis of acute organ rejection in renal transplantation. Currently, the TxGNN model has **no predicted new indications** for this drug, and the evidence pack contains significant data gaps that must be resolved before repurposing analysis can proceed.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Prophylaxis of acute organ rejection in renal transplantation (known; not populated in evidence pack) |
| Predicted New Indication | — (No TxGNN predictions available) |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (No predictions or studies to evaluate) |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 1 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

> Currently, detailed mechanism of action data is not available in the evidence pack. Based on publicly known information, Basiliximab (brand name: Simulect) is a chimeric (murine/human) monoclonal antibody that binds specifically to the interleukin-2 receptor α chain (CD25) on the surface of activated T lymphocytes. By blocking IL-2 binding, it inhibits IL-2-mediated T-cell proliferation, a critical step in the cellular immune response involved in allograft rejection.

This mechanism — selective immunosuppression via IL-2 pathway inhibition — has theoretical applicability to other immune-mediated conditions such as graft-versus-host disease (GvHD), autoimmune disorders, and certain T-cell-mediated inflammatory diseases. However, **the TxGNN model has not generated any predicted indications** for Basiliximab in the current run, which may be due to incomplete input data (e.g., missing DrugBank mapping in the knowledge graph) or the drug's highly specialised biologic nature limiting graph-based inference.

Without TxGNN predictions, no mechanistic bridging analysis between an original and a new indication can be performed at this time.

---

## Clinical Trial Evidence

Currently no predicted indication is available from TxGNN; therefore, targeted clinical trial evidence cannot be retrieved.

> To populate this section, TxGNN predictions must first be generated, after which ClinicalTrials.gov and ICTRP queries can be conducted for the predicted disease(s).

---

## Literature Evidence

Currently no predicted indication is available from TxGNN; therefore, targeted literature evidence cannot be retrieved.

---

## Malaysia Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|------|------|------|------|
| (Not available in evidence pack) | (Not available) | (Not available) | (Not available) |

> **Note:** The NPRA query returned 1 registration record for Basiliximab, but the detailed licence fields (authorization number, product name, dosage form, approved indication) were not populated in the evidence pack. These need to be retrieved from the NPRA database.

---

## Safety Considerations

> Please refer to the package insert for safety information.
>
> The evidence pack does not contain key warnings, contraindications, or drug interaction data for Basiliximab. These are classified as **Blocking** data gaps (DG001) that must be resolved before safety assessment can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack for Basiliximab contains critical data gaps — no TxGNN predictions have been generated, the mechanism of action field is empty, safety data (warnings and contraindications) are missing, and the Malaysia licence details are incomplete. Without at least one predicted new indication, the repurposing evaluation pipeline cannot proceed.

**To proceed, the following is needed:**

1. **Resolve DG001 (Blocking):** Retrieve package insert warnings and contraindications from the NPRA website or manufacturer documentation
2. **Resolve DG002 (High):** Query DrugBank API for Basiliximab's mechanism of action, targets, and pharmacological classification
3. **Populate Malaysia licence details:** Complete the NPRA registration record (authorization number, product name, dosage form, approved indication text)
4. **Re-run TxGNN prediction pipeline:** Ensure Basiliximab (DB00074) is correctly mapped in the knowledge graph and re-execute both KG and DL prediction methods
5. **Once predictions are available:** Collect clinical trial and literature evidence for the top predicted indication(s)

---

*Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

